How does race and ethnicity effect the precision treatment of asthma?

References

• Martinez FD, Vercelli D. Asthma. Lancet. 2013 Oct 19;382(9901):1360–1372.
   PubMed Web of Science ®Google Scholar
• National Asthma E, Prevention P. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007 Nov;120(5):S94–138.
   PubMed Web of Science ®Google Scholar
• Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. NCHS Data Brief. 2012 May;(94):1–8.
   PubMedGoogle Scholar
• Gold DR, Adamkiewicz G, Arshad SH, et al. NIAID, NIEHS, NHLBI, and MCAN workshop report: the indoor environment and childhood asthma-implications for home environmental intervention in asthma prevention and management. J Allergy Clin Immunol. 2017 Oct;140(4):933–949.
   PubMed Web of Science ®Google Scholar
• Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy. 2004 May;59(5):469–478.
   PubMed Web of Science ®Google Scholar
• Szentpetery SE, Forno E, Canino G, et al. Asthma in puerto ricans: lessons from a high-risk population. J Allergy Clin Immunol. 2016 Dec;138(6):1556–1558.
   PubMed Web of Science ®Google Scholar
• Rumpel JA, Ahmedani BK, Peterson EL, et al. Genetic ancestry and its association with asthma exacerbations among African American subjects with asthma. J Allergy Clin Immunol. 2012 Dec;130(6):1302–1306.
   PubMed Web of Science ®Google Scholar
• Apter AJ, Boston RC, George M, et al. Modifiable barriers to adherence to inhaled steroids among adults with asthma: it’s not just black and white. J Allergy Clin Immunol. 2003 Jun;111(6):1219–1226.
   PubMed Web of Science ®Google Scholar
• Sin DD, Man J, Sharpe H, et al. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA. 2004 Jul 21;292(3):367–376.
   PubMed Web of Science ®Google Scholar
• Schleimer RP, Bochner BS. The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol. 1994 Dec;94(6 Pt 2):1202–1213.
   PubMed Web of Science ®Google Scholar
• Druilhe A, Letuve S, Pretolani M. Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis. 2003 Oct;8(5):481–495.
   PubMed Web of Science ®Google Scholar
• Jonas DE, Wines RCM, DelMonte M, et al. Drug class review: controller medications for asthma: final update 1 report. Drug Class Rev. Portland (OR). 2011 Apr.
   Google Scholar
• McGregor MC, Krings JG, Nair P, et al. Role of biologics in asthma. Am J Respir Crit Care Med. 2019 Feb 15;199(4):433–445.
   PubMed Web of Science ®Google Scholar
• Burchard EG, Oh SS, Foreman MG, et al. Moving toward true inclusion of racial/ethnic minorities in federally funded studies. A key step for achieving respiratory health equality in the United States. Am J Respir Crit Care Med. 2015 Mar 1;191(5):514–521.
   PubMed Web of Science ®Google Scholar
• Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med. 1995 Aug 24;333(8):499–506.
   PubMed Web of Science ®Google Scholar
• Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol. 2006 Jan;117(1):18–24. quiz 25.
   PubMed Web of Science ®Google Scholar
• Billington CK, Penn RB, Hall IP. Beta2 Agonists. Handb Exp Pharmacol. 2017;237:23–40.
   PubMedGoogle Scholar
• Johnson M. Beta2-adrenoceptors: mechanisms of action of beta2-agonists. Paediatr Respir Rev. 2001 Mar;2(1):57–62.
   PubMedGoogle Scholar
• Robison GA, Butcher RW, Sutherland EW. Cyclic AMP. Annu Rev Biochem. 1968;37:149–174.
   PubMed Web of Science ®Google Scholar
• Nieminen MM, Kaprio J, Koskenvuo M. A population-based study of bronchial asthma in adult twin pairs. Chest. 1991 Jul;100(1):70–75.
   PubMed Web of Science ®Google Scholar
• Fagnani C, Annesi-Maesano I, Brescianini S, et al. Heritability and shared genetic effects of asthma and hay fever: an Italian study of young twins. Twin Res Hum Genet. 2008 Apr;11(2):121–131.
   PubMed Web of Science ®Google Scholar
• McGeachie MJ, Stahl EA, Himes BE, et al. Polygenic heritability estimates in pharmacogenetics: focus on asthma and related phenotypes. Pharmacogenet Genomics. 2013 Jun;23(6):324–328.
   PubMed Web of Science ®Google Scholar
• Naqvi M, Thyne S, Choudhry S, et al. Ethnic-specific differences in bronchodilator responsiveness among African Americans, puerto ricans, and Mexicans with asthma. J Asthma. 2007 Oct;44(8):639–648.
   PubMed Web of Science ®Google Scholar
• Burchard EG, Avila PC, Nazario S, et al. Lower bronchodilator responsiveness in puerto rican than in Mexican subjects with asthma. Am J Respir Crit Care Med. 2004 Feb 1;169(3):386–392. • First study to suggest that different subgroups of Latinos may respond differently to asthma medication.
   PubMed Web of Science ®Google Scholar
• Choudhry S, Ung N, Avila PC, et al. Pharmacogenetic differences in response to albuterol between puerto ricans and Mexicans with asthma. Am J Respir Crit Care Med. 2005 Mar 15;171(6):563–570.
   PubMed Web of Science ®Google Scholar
• Salari K, Choudhry S, Tang H, et al. Genetic admixture and asthma-related phenotypes in Mexican American and puerto rican asthmatics. Genet Epidemiol. 2005 Jul;29(1):76–86.
   PubMed Web of Science ®Google Scholar
• Tsai HJ, Shaikh N, Kho JY, et al. Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet. 2006 Jun;119(5):547–557.
   PubMed Web of Science ®Google Scholar
• Choudhry S, Que LG, Yang Z, et al. GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenet Genomics. 2010 Jun;20(6):351–358.
   PubMed Web of Science ®Google Scholar
• Mak ACY, White MJ, Eckalbar WL, et al. Whole-genome sequencing of pharmacogenetic drug response in racially diverse children with asthma. Am J Respir Crit Care Med. 2018 Jun 15;197(12):1552–1564. • First study to use whole genome sequencing to identify genetic predictors of short-acting beta-agonist response; the study population comprised Latinos and African Americans.
   PubMed Web of Science ®Google Scholar
• Padhukasahasram B, Yang JJ, Levin AM, et al. Gene-based association identifies SPATA13-AS1 as a pharmacogenomic predictor of inhaled short-acting beta-agonist response in multiple population groups. Pharmacogenomics J. 2014 Aug;14(4):365–371. • This study used individuals without asthma to identify genetic predictors of short-acting beta-agonist bronchodilator response and then replicated its findings in individuals with asthma.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Brennan MD, Woodward ND, et al. Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder. Schizophr Res. 2008 Dec;106(2–3):258–264.
   PubMed Web of Science ®Google Scholar
• Minchin RF, Lewis A, Mitchell D, et al. Sulfotransferase 4A1. Int J Biochem Cell Biol. 2008;40(12):2686–2691.
   PubMed Web of Science ®Google Scholar
• Sidharthan NP, Butcher NJ, Mitchell DJ, et al. Expression of the orphan cytosolic sulfotransferase SULT4A1 and its major splice variant in human tissues and cells: dimerization, degradation and polyubiquitination. PLoS One. 2014;9(7):e101520.
   PubMed Web of Science ®Google Scholar
• Spear ML, Hu D, Pino-Yanes M, et al. A genome-wide association and admixture mapping study of bronchodilator drug response in African Americans with asthma. Pharmacogenomics J. 2019 Jun;19(3):249–259.
   PubMed Web of Science ®Google Scholar
• Derom EY, Pauwels RA. Time course of bronchodilating effect of inhaled formoterol, a potent and long acting sympathomimetic. Thorax. 1992 Jan;47(1):30–33.
   PubMed Web of Science ®Google Scholar
• Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax. 1988 Sep;43(9):674–678.
   PubMed Web of Science ®Google Scholar
• Lofdahl CG, Svedmyr N. Formoterol fumarate, a new beta 2-adrenoceptor agonist acute studies of selectivity and duration of effect after inhaled and oral administration. Allergy. 1989 May;44(4):264–271.
   PubMed Web of Science ®Google Scholar
• Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol. 2002 Dec;110(6):S322–8.
   PubMedGoogle Scholar
• Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993 Apr 17;306(6884):1034–1037.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006 Jun 20;144(12):904–912.
   PubMed Web of Science ®Google Scholar
• Ortega VE, Meyers DA. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J Allergy Clin Immunol. 2014 Jan;133(1):16–26.
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, et al. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006 Jan;129(1):15–26.
   PubMed Web of Science ®Google Scholar
• Hasford J, Virchow JC. Excess mortality in patients with asthma on long-acting beta2-agonists. Eur Respir J. 2006 Nov;28(5):900–902.
   PubMed Web of Science ®Google Scholar
• Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ. 2005 Jan 15;330(7483):117.
   PubMedGoogle Scholar
• Peters SP, Prenner BM, Mezzanotte WS, et al. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy Asthma Proc. 2008 Sep-Oct;29(5):499–516.
   PubMed Web of Science ®Google Scholar
• Sears MR, Ottosson A, Radner F, et al. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J. 2009 Jan;33(1):21–32.
   PubMed Web of Science ®Google Scholar
• Ducharme FM, Ni Chroinin M, Greenstone I, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010 May;12(5):CD005535.
   Google Scholar
• Wells KE, Peterson EL, Ahmedani BK, et al. The relationship between combination inhaled corticosteroid and long-acting beta-agonist use and severe asthma exacerbations in a diverse population. J Allergy Clin Immunol. 2012 May;129(5):1274–1279 e2.
   PubMed Web of Science ®Google Scholar
• Bailey W, Castro M, Matz J, et al. Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone. Curr Med Res Opin. 2008 Jun;24(6):1669–1682.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Castro M, Lehman E, et al. Impact of race on asthma treatment failures in the asthma clinical research network. Am J Respir Crit Care Med. 2011 Dec 1;184(11):1247–1253.
   PubMed Web of Science ®Google Scholar
• Rand CS, Wise RA, Nides M, et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis. 1992 Dec;146(6):1559–1564.
   PubMed Web of Science ®Google Scholar
• Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999 Jun;21(6):1074–1090. discussion 1073.
   PubMed Web of Science ®Google Scholar
• Bender B, Wamboldt FS, O’Connor SL, et al. Measurement of children’s asthma medication adherence by self report, mother report, canister weight, and doser CT. Ann Allergy Asthma Immunol. 2000 Nov;85(5):416–421.
   PubMed Web of Science ®Google Scholar
• Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047.
   PubMed Web of Science ®Google Scholar
• Lemanske RF Jr., Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010 Mar 18;362(11):975–985.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Szefler SJ, Ortega VE, et al. Step-up therapy in black children and adults with poorly controlled asthma. N Engl J Med. 2019 Sep 26;381(13):1227–1239.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Postma DS, Lawrance RM, et al. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet. 2007 Dec 22;370(9605):2118–2125.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Yancey SW, Baitinger LA, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol. 2006 Oct;118(4):809–816.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet. 2009 Nov 21;374(9703):1754–1764.
   PubMed Web of Science ®Google Scholar
• Basu K, Palmer CN, Tavendale R, et al. Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol. 2009 Dec;124(6):1188–94 e3.
   PubMed Web of Science ®Google Scholar
• Palmer CN, Lipworth BJ, Lee S, et al. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax. 2006 Nov;61(11):940–944.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Lehman E, Lazarus SC, et al. Beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006 Mar 1;173(5):519–526.
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009 Apr 1;179(7):549–558.
   PubMed Web of Science ®Google Scholar
• Ortega VE, Hawkins GA, Moore WC, et al. Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting beta agonist treatment in a multiethnic asthma population: a genetic study. Lancet Respir Med. 2014 Mar;2(3):204–213.
   PubMed Web of Science ®Google Scholar
• Peters SP, Kunselman SJ, Icitovic N, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med. 2010 Oct 28;363(18):1715–1726.
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Yawn BP, Fuhlbrigge AL, et al. Anticholinergic vs long-acting beta-agonist in combination with inhaled corticosteroids in black adults with asthma: the BELT randomized clinical trial. JAMA. 2015 Oct 27;314(16):1720–1730.
   PubMed Web of Science ®Google Scholar
• Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2012 May;16(5):CD002314.
   Google Scholar
• Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011 May 5;364(18):1695–1707.
   PubMed Web of Science ®Google Scholar
• Peters SP. Leukotriene receptor antagonists in asthma therapy. J Allergy Clin Immunol. 2003 Jan;111(1):S62–70.
   PubMedGoogle Scholar
• Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med. 2007 Nov 1;357(18):1841–1854.
   PubMed Web of Science ®Google Scholar
• Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Iimmunol. 2004 Aug 1;173(3):1503–1510.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med. 1997 Sep 15;127(6):472–480.
   PubMed Web of Science ®Google Scholar
• Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 1991 May 4;337(8749):1062–1063.
   PubMed Web of Science ®Google Scholar
• Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med. 1999 Jan 21;340(3):197–206.
   PubMed Web of Science ®Google Scholar
• Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999 Jun;22(2):168–170.
   PubMed Web of Science ®Google Scholar
• Via M, Tcheurekdjian H, Gonzalez Burchard E. Role of interactions in pharmacogenetic studies: leukotrienes in asthma. Pharmacogenomics. 2013 Jun;14(8):923–929.
   PubMed Web of Science ®Google Scholar
• Lima JJ, Zhang S, Grant A, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006 Feb 15;173(4):379–385.
   PubMed Web of Science ®Google Scholar
• Dahlin A, Qiu W, Litonjua AA, et al. The phosphatidylinositide 3-kinase (PI3K) signaling pathway is a determinant of zileuton response in adults with asthma. Pharmacogenomics J. 2018 Sep;18(5):665–677.
   PubMed Web of Science ®Google Scholar
• Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009 Feb;19(2):129–138.
   PubMed Web of Science ®Google Scholar
• Dahlin A, Litonjua A, Lima JJ, et al. Genome-wide association study identifies novel pharmacogenomic loci for therapeutic response to montelukast in asthma. PLoS One. 2015;10(6):e0129385.
   PubMed Web of Science ®Google Scholar
• Dahlin A, Litonjua A, Irvin CG, et al. Genome-wide association study of leukotriene modifier response in asthma. Pharmacogenomics J. 2016 Apr;16(2):151–157.
   PubMed Web of Science ®Google Scholar
• Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388–392.
   PubMed Web of Science ®Google Scholar
• Kerstjens HA, Brand PL, Hughes MD, et al. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch chronic non-specific lung disease study group. N Engl J Med. 1992 Nov 12;327(20):1413–1419.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003 Mar 29;361(9363):1071–1076.
   PubMed Web of Science ®Google Scholar
• De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev. 2003 Aug;24(4):488–522.
   PubMed Web of Science ®Google Scholar
• Adcock IM, Ito K, Barnes PJ. Glucocorticoids: effects on gene transcription. Proc Am Thorac Soc. 2004;1(3):247–254.
   PubMedGoogle Scholar
• Chanez P, Bourdin A, Vachier I, et al. Effects of inhaled corticosteroids on pathology in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1(3):184–190.
   PubMedGoogle Scholar
• Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2003 Jan;111(1):3–22. quiz 23.
   PubMed Web of Science ®Google Scholar
• Sobande PO, Kercsmar CM. Inhaled corticosteroids in asthma management. Respir Care. 2008 May;53(5):625–633. discussion 633-4.
   PubMed Web of Science ®Google Scholar
• Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. A J Physiol. 1995 Jan;268(1 Pt 1):L41–6.
   PubMed Web of Science ®Google Scholar
• Moore PE, Laporte JD, Gonzalez S, et al. Glucocorticoids ablate IL-1beta-induced beta-adrenergic hyporesponsiveness in human airway smooth muscle cells. A J Physiol. 1999 Nov;277(5):L932–42.
   PubMed Web of Science ®Google Scholar
• Jin Y, Hu D, Peterson EL, et al. Dual-specificity phosphatase 1 as a pharmacogenetic modifier of inhaled steroid response among asthmatic patients. JAllergyClinImmunol. 2010 Sept;126(3):618–625.
   Google Scholar
• Martin RJ, Szefler SJ, King TS, et al. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol. 2007 Jan;119(1):73–80.
   PubMed Web of Science ®Google Scholar
• Gould W, Peterson EL, Karungi G, et al. Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma. J Allergy Clin Immunol. 2010 Dec;126(6):1131–1138.
   PubMed Web of Science ®Google Scholar
• Minto C, Li B, Tattam B, et al. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation–intersubject variability in systemic absorption from the lung. Br J Clin Pharmacol. 2000 Aug;50(2):116–124.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J. 1996 Apr;9(4):636–642.
   PubMed Web of Science ®Google Scholar
• Park HW, Dahlin A, Tse S, et al. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J Allergy Clin Immunol. 2014 Mar;133(3):664–9 e5.
   PubMed Web of Science ®Google Scholar
• Dahlin A, Denny J, Roden DM, et al. CMTR1 is associated with increased asthma exacerbations in patients taking inhaled corticosteroids. Immun Inflamm Dis. 2015 Dec;3(4):350–359.
   PubMed Web of Science ®Google Scholar
• Wang Y, Tong C, Wang Z, et al. Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma. Pharmacogenomics J. 2015 Oct;15(5):422–429.
   PubMed Web of Science ®Google Scholar
• Tantisira KG, Damask A, Szefler SJ, et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med. 2012 Jun 15;185(12):1286–1291.
   PubMed Web of Science ®Google Scholar
• Tantisira KG, Lasky-Su J, Harada M, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med. 2011 Sep 29;365(13):1173–1183.
   PubMed Web of Science ®Google Scholar
• Qiu W, Rogers AJ, Damask A, et al. Pharmacogenomics: novel loci identification via integrating gene differential analysis and eQTL analysis. Hum Mol Genet. 2014 Sep 15;23(18):5017–5024.
   PubMed Web of Science ®Google Scholar
• Grundberg E, Adoue V, Kwan T, et al. Global analysis of the impact of environmental perturbation on cis-regulation of gene expression. PLoS Genet. 2011 Jan 20;7(1):e1001279.
   PubMed Web of Science ®Google Scholar
• Hawkins GA, Lazarus R, Smith RS, et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J Allergy Clin Immunol. 2009 Jun;123(6):1376–83 e7.
   PubMed Web of Science ®Google Scholar
• Levin AM, Gui H, Hernandez-Pacheco N, et al. Integrative approach identifies corticosteroid response variant in diverse populations with asthma. J Allergy Clin Immunol. 2019 May;143(5):1791–1802.
   PubMed Web of Science ®Google Scholar
• Himes BE, Jiang X, Wagner P, et al. RNA-Seq transcriptome profiling identifies CRISPLD2 as a glucocorticoid responsive gene that modulates cytokine function in airway smooth muscle cells. PLoS One. 2014;9(6):e99625.
   PubMed Web of Science ®Google Scholar
• Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004 Jul 1;13(13):1353–1359.
   PubMed Web of Science ®Google Scholar
• Tantisira KG, Hwang ES, Raby BA, et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18099–18104.
   PubMed Web of Science ®Google Scholar
• Hernandez-Pacheco N, Farzan N, Francis B, et al. Genome-wide association study of inhaled corticosteroid response in admixed children with asthma. Clin Exp Allergy. 2019 Jun;49(6):789–798.
   PubMed Web of Science ®Google Scholar
• Vijverberg SJ, Koster ES, Tavendale R, et al. ST13 polymorphisms and their effect on exacerbations in steroid-treated asthmatic children and young adults. Clin Exp Allergy. 2015 Jun;45(6):1051–1059.
   PubMed Web of Science ®Google Scholar
• Mougey EB, Chen C, Tantisira KG, et al. Pharmacogenetics of asthma controller treatment. Pharmacogenomics J. 2013 Jun;13(3):242–250.
   PubMed Web of Science ®Google Scholar
• Park HW, Tantisira KG, Weiss ST. Pharmacogenomics in asthma therapy: where are we and where do we go? Annu Rev Pharmacol Toxicol. 2015;55:129–147.
   PubMed Web of Science ®Google Scholar
• Wells KE, Cajigal S, Peterson EL, et al. Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among asthmatic subjects. J Allergy Clin Immunol. 2016 May;137(5):1364–1369 e2.
   PubMed Web of Science ®Google Scholar
• Rosenberg HF. Eosinophil-derived neurotoxin/RNase 2: connecting the past, the present and the future. Curr Pharm Biotechnol. 2008 Jun;9(3):135–140.
   PubMed Web of Science ®Google Scholar
• Mosteller M, Hosking L, Murphy K, et al. No evidence of large genetic effects on steroid response in asthma patients. J Allergy Clin Immunol. 2017 Mar;139(3):797–803 e7.
   PubMed Web of Science ®Google Scholar
• Fuentes AV, Pineda MD, Venkata KCN. Comprehension of top 200 prescribed drugs in the US as a resource for pharmacy teaching, training and practice. Pharmacy (Basel). 2018 May 14;6:2.
   Google Scholar
• Papi A, Brightling C, Pedersen SE, et al. Asthma. Lancet. 2018 Feb 24;391(10122):783–800.
   PubMed Web of Science ®Google Scholar
• Apter AJ, Reisine ST, Affleck G, et al. Adherence with twice-daily dosing of inhaled steroids. Socioeconomic and health-belief differences. Am J RespirCrit Care Med. 1998 Jun;157(6 Pt 1):1810–1817.
   PubMed Web of Science ®Google Scholar
• Wells K, Pladevall M, Peterson EL, et al. Race-ethnic differences in factors associated with inhaled steroid adherence among adults with asthma. Am J Respir Crit Care Med. 2008 Dec 15;178(12):1194–1201.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Burchard EG, Choudhry S, et al. Differences in allergic sensitization by self-reported race and genetic ancestry. J Allergy Clin Immunol. 2008 Oct;122(4):820–827.
   PubMed Web of Science ®Google Scholar
• Pino-Yanes M, Thakur N, Gignoux CR, et al. Genetic ancestry influences asthma susceptibility and lung function among Latinos. J Allergy Clin Immunol. 2015 Jan;135(1):228–235.
   PubMed Web of Science ®Google Scholar
• Baran Y, Pasaniuc B, Sankararaman S, et al. Fast and accurate inference of local ancestry in Latino populations. Bioinformatics. 2012 May 15;28(10):1359–1367.
   PubMed Web of Science ®Google Scholar
• Yang JJ, Li J, Buu A, et al. Efficient inference of local ancestry. Bioinformatics. 2013 Nov 1;29(21):2750–2756.
   PubMed Web of Science ®Google Scholar
• Tishkoff SA, Reed FA, Friedlaender FR, et al. The genetic structure and history of Africans and African Americans. Science. 2009 May 22;324(5930):1035–1044.
   PubMed Web of Science ®Google Scholar
• Torgerson DG, Ampleford EJ, Chiu GY, et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. NatGenet. 2011 Sept;43(9):887–892.
   Google Scholar
• Sleiman PM, Flory J, Imielinski M, et al. Variants of DENND1B associated with asthma in children. N Engl J Med. 2010 Jan 7;362(1):36–44.
   PubMedGoogle Scholar
• Galanter J, Choudhry S, Eng C, et al. ORMDL3 gene is associated with asthma in three ethnically diverse populations. Am J Respir Crit Care Med. 2008 Jun 1;177(11):1194–1200.
   PubMed Web of Science ®Google Scholar
• Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med. 2011 Mar 24;364(12):1126–1133.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics. 2006 Feb;16(2):101–110.
   PubMed Web of Science ®Google Scholar
• Carson P, Ziesche S, Johnson G, et al. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-heart failure trial study group. J Card Fail. 1999 Sep;5(3):178–187.
   PubMedGoogle Scholar
• Zhou HH, Koshakji RP, Silberstein DJ, et al. Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med. 1989 Mar 2;320(9):565–570.
   PubMed Web of Science ®Google Scholar
• Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018 Sep;19(9):581–590.
   PubMed Web of Science ®Google Scholar
• Marquez-Luna C, Loh PR, South Asian Type 2 Diabetes (SAT2D) Consortium, et al. Multiethnic polygenic risk scores improve risk prediction in diverse populations. Genet Epidemiol. 2017 Dec;41(8):811–823.
   PubMed Web of Science ®Google Scholar
• Marden JR, Walter S, Tchetgen Tchetgen EJ, et al. Validation of a polygenic risk score for dementia in black and white individuals. Brain Behav. 2014 Sep;4(5):687–697.
   PubMed Web of Science ®Google Scholar
• Cooke JN, Ng MC, Palmer ND, et al. Genetic risk assessment of type 2 diabetes-associated polymorphisms in African Americans. Diabetes Care. 2012 Feb;35(2):287–292.
   PubMed Web of Science ®Google Scholar
• Oh SS, Galanter J, Thakur N, et al. Diversity in clinical and biomedical research: a promise yet to be fulfilled. PLoS Med. 2015 Dec;12(12):e1001918.
   PubMed Web of Science ®Google Scholar
• Bustamante CD, Burchard EG, Francisco M. Genomics for the world. Nature. 2011 Jul 14;475(7355):163–165.
   PubMed Web of Science ®Google Scholar
• Burchard EG, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med. 2003 Mar 20;348(12):1170–1175.
   PubMed Web of Science ®Google Scholar
• Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004 Dec;114(6):1288–1293.
   PubMed Web of Science ®Google Scholar
• Berry A, Busse WW. Biomarkers in asthmatic patients: has their time come to direct treatment? J Allergy Clin Immunol. 2016 May;137(5):1317–1324.
   PubMed Web of Science ®Google Scholar
• Arron JR, Izuhara K. Asthma biomarkers: what constitutes a ‘gold standard’? Thorax. 2015 Feb;70(2):105–107.
   PubMed Web of Science ®Google Scholar
• Darveaux J, Busse WW. Biologics in asthma–the next step toward personalized treatment. J Allergy Clin Immunol Pract. 2015 Mar–Apr;3(2):152–160. quiz 161.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Nelson HS, Kraft M, et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med. 2010 Apr 1;181(7):676–687.
   PubMed Web of Science ®Google Scholar